Exelixis (EXEL)

Nasdaq Health Care Biotechnology S&P MidCap 400

$69.57

+0.86 (+1.25%)

Close of Nov 06, 2026 · end-of-day data

Source: Exelixis's 10-K / 10-Q XBRL data on SEC EDGAR · fetched Nov 06, 2026

Revenue, net income & free cash flow

Income statement

fiscal years · USD

Fiscal year	FY2016	FY2017	FY2018	FY2020	FY2021	FY2021	FY2022	FY2023	FY2025	FY2026
Revenue	$191.45M	$452.48M	$853.83M	$967.77M	$987.54M	$1.43B	$1.61B	$1.83B	$2.17B	$2.32B
Cost of revenue	$6.55M	$15.07M	$26.35M	$33.10M	$36.27M	$52.87M	$57.91M	$72.55M	$76.22M	$83.70M
Gross profit	$184.90M	$437.41M	$827.48M	$934.68M	$951.27M	$1.38B	$1.55B	$1.76B	$2.09B	$2.24B
Research & development	$95.97M	$112.17M	$182.26M	$336.96M	$547.85M	$693.72M	$891.81M	$1.04B	$910.41M	$825.00M
Selling, general & admin	$116.14M	$159.33M	$206.37M	$228.24M	$293.36M	$401.71M	$459.86M	$542.71M	$492.13M	$518.73M
Operating income	-$28.12M	$165.91M	$438.86M	$369.47M	$110.06M	$286.67M	$201.48M	$170.88M	$604.62M	$872.19M
Interest expense	$33.06M	$8.68M	$0	$0	—	—	—	—	—	—
Pre-tax income	-$70.22M	$158.58M	$452.09M	$398.11M	$130.84M	—	—	—	—	—
Income tax	$0	$4.35M	-$237.98M	$77.10M	$19.06M	$63.09M	$52.07M	$49.76M	$160.37M	$158.64M
Net income	-$70.22M	$154.23M	$690.07M	$321.01M	$111.78M	$231.06M	$182.28M	$207.76M	$521.27M	$782.57M
EBITDA	-$27.12M	$167.10M	$443.77M	$377.82M	$119.20M	$300.30M	$222.36M	$196.60M	$633.42M	$901.25M
EPS (basic)	$-0.28	$0.52	$2.32	$1.06	$0.36	$0.73	$0.57	$0.65	$1.80	$2.88
EPS (diluted)	$-0.28	$0.49	$2.21	$1.02	$0.35	$0.72	$0.56	$0.65	$1.76	$2.78
Diluted shares	250.53M	312.00M	312.80M	315.01M	318.00M	322.36M	324.56M	321.46M	296.13M	281.86M
Gross margin	96.6%	96.7%	96.9%	96.6%	96.3%	96.3%	96.4%	96.0%	96.5%	96.4%
Operating margin	-14.7%	36.7%	51.4%	38.2%	11.1%	20.0%	12.5%	9.3%	27.9%	37.6%
Net margin	-36.7%	34.1%	80.8%	33.2%	11.3%	16.1%	11.3%	11.4%	24.0%	33.7%

Balance sheet

fiscal years · USD

Fiscal year	FY2016	FY2017	FY2018	FY2020	FY2021	FY2021	FY2022	FY2023	FY2025	FY2026
Cash & equivalents	$151.69M	$183.16M	$314.77M	$266.50M	$319.22M	$647.17M	$501.19M	$262.99M	$217.37M	$482.49M
Short-term investments	$268.12M	$204.61M	$378.56M	$585.74M	$887.32M	$819.90M	$807.27M	$732.31M	$893.90M	$576.60M
Receivables	$40.44M	$77.30M	$162.77M	$119.07M	$160.88M	$282.65M	$214.78M	$237.41M	$265.44M	$286.92M
Inventory	$3.34M	$6.66M	$9.84M	$12.89M	$20.97M	$27.49M	$33.30M	$17.32M	$22.39M	$21.69M
Total current assets	$469.00M	$484.87M	$897.02M	$1.01B	$1.45B	$1.83B	$1.62B	$1.32B	$1.47B	$1.44B
Goodwill	$63.68M	$63.68M	$63.68M	$63.68M	$63.68M	$63.68M	$63.68M	$63.68M	$63.68M	$63.68M
Total assets	$595.74M	$655.29M	$1.42B	$1.89B	$2.14B	$2.62B	$3.07B	$2.94B	$2.95B	$2.84B
Total current liabilities	$268.79M	$115.17M	$105.47M	$142.75M	$204.66M	$337.59M	$324.36M	$394.28M	$403.77M	$405.64M
Short-term debt	$189.12M	—	—	—	—	—	—	—	—	—
Long-term debt	$0	$0	—	—	—	—	—	—	—	—
Total debt	$189.12M	$0	—	—	—	—	—	—	—	—
Total liabilities	$506.42M	$370.33M	$134.83M	$199.70M	$258.22M	$405.62M	$583.06M	$678.45M	$703.49M	$683.10M
Shareholders' equity	$89.32M	$284.96M	$1.29B	$1.69B	$1.88B	$2.21B	$2.49B	$2.26B	$2.24B	$2.16B

Cash flow

fiscal years · USD

Fiscal year	FY2016	FY2017	FY2018	FY2020	FY2021	FY2021	FY2022	FY2023	FY2025	FY2026
Operating cash flow	$206.30M	$165.61M	$415.72M	$526.96M	$208.98M	$400.80M	$362.61M	$333.32M	$699.97M	$884.27M
Capital expenditures	$1.70M	$21.14M	$33.30M	$12.83M	$30.34M	$54.23M	$27.71M	$40.47M	$28.43M	$8.43M
Free cash flow	$204.59M	$144.47M	$382.42M	$514.12M	$178.64M	$346.58M	$334.91M	$292.86M	$671.54M	$875.84M
Investing cash flow	-$216.05M	$36.80M	-$297.85M	-$587.25M	-$131.22M	-$42.88M	-$524.41M	-$26.95M	-$116.78M	$350.44M
Financing cash flow	$19.80M	-$169.93M	$9.69M	$12.55M	-$25.13M	-$14.80M	$586.00K	-$546.05M	-$628.81M	-$969.59M
Share buybacks	—	—	—	—	—	$0	$0	$550.38M	$652.03M	$947.51M
Stock-based compensation	$22.91M	$23.94M	$40.63M	$56.60M	$105.07M	$119.82M	$107.57M	$106.34M	$93.84M	$112.98M
Depreciation & amortization	$1.00M	$1.19M	$4.92M	$8.35M	$9.14M	$13.63M	$20.88M	$25.72M	$28.80M	$29.05M

Income statement

quarters · USD

Quarter ended	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Jan 2025	Apr 2025	Jul 2025	Oct 2025	Jan 2026	Apr 2026	Jul 2026	Oct 2026
Revenue	$479.65M	$425.23M	$637.18M	$539.54M	$566.75M	$555.45M	$568.26M	$597.75M	$598.66M	$610.81M	$628.69M	$658.70M
Cost of revenue	$21.75M	$21.26M	$17.67M	$17.33M	$19.96M	$19.17M	$19.47M	$18.57M	$26.48M	$19.95M	$20.66M	$26.23M
Gross profit	$457.90M	$403.97M	$619.51M	$522.21M	$546.79M	$536.27M	$548.79M	$579.18M	$572.18M	$590.86M	$608.03M	$632.46M
Research & development	$244.67M	$227.69M	$211.15M	$222.57M	$249.00M	$212.23M	$200.36M	$199.16M	$213.25M	$199.92M	$211.99M	$209.48M
Selling, general & admin	$131.44M	$113.98M	$132.01M	$111.80M	$134.33M	$137.18M	$134.86M	$123.66M	$123.02M	$139.60M	$147.63M	$154.56M
Operating income	$81.79M	$29.46M	$275.87M	$136.07M	$163.21M	$186.86M	$213.58M	$236.54M	$235.22M	$251.34M	$248.41M	$268.42M
Income tax	$17.52M	$11.95M	$66.73M	$36.78M	$44.91M	$46.07M	$45.57M	$58.84M	$8.16M	$57.22M	$50.63M	$64.69M
Net income	$85.52M	$37.32M	$226.12M	$117.97M	$139.86M	$159.62M	$184.85M	$193.58M	$244.53M	$210.47M	$212.05M	$218.09M
EBITDA	$88.31M	$35.84M	$283.20M	$143.53M	$170.85M	$194.20M	$220.92M	$243.96M	$242.16M	$258.29M	$255.40M	$275.36M
EPS (basic)	$0.27	$0.12	$0.78	$0.41	$0.49	$0.57	$0.68	$0.72	$0.91	$0.81	$0.85	$0.88
EPS (diluted)	$0.27	$0.12	$0.77	$0.40	$0.48	$0.55	$0.65	$0.69	$0.88	$0.79	$0.82	$0.85
Diluted shares	-2.81M	305.53M	293.97M	291.48M	-862.00K	288.18M	284.39M	278.54M	-1.84M	267.32M	259.68M	255.75M
Gross margin	95.5%	95.0%	97.2%	96.8%	96.5%	96.5%	96.6%	96.9%	95.6%	96.7%	96.7%	96.0%
Operating margin	17.1%	6.9%	43.3%	25.2%	28.8%	33.6%	37.6%	39.6%	39.3%	41.1%	39.5%	40.8%
Net margin	17.8%	8.8%	35.5%	21.9%	24.7%	28.7%	32.5%	32.4%	40.8%	34.5%	33.7%	33.1%

Balance sheet

quarters · USD

Quarter ended	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Jan 2025	Apr 2025	Jul 2025	Oct 2025	Jan 2026	Apr 2026	Jul 2026	Oct 2026
Cash & equivalents	$262.99M	$259.56M	$198.46M	$258.35M	$217.37M	$183.75M	$164.43M	$376.30M	$482.49M	$226.15M	$281.45M	$304.77M
Short-term investments	$732.31M	$703.70M	$803.54M	$930.82M	$893.90M	$847.56M	$626.66M	$612.24M	$576.60M	$551.05M	$557.94M	$587.24M
Receivables	$237.41M	$240.58M	$396.58M	$269.71M	$265.44M	$281.64M	$292.35M	$309.73M	$286.92M	$328.95M	$322.21M	$328.47M
Inventory	$17.32M	$21.11M	$20.61M	$21.01M	$22.39M	$24.85M	$23.48M	$27.40M	$21.69M	$26.61M	$28.73M	$29.87M
Total current assets	$1.32B	$1.29B	$1.48B	$1.55B	$1.47B	$1.40B	$1.18B	$1.40B	$1.44B	$1.21B	$1.25B	$1.32B
Goodwill	$63.68M	$63.68M	$63.68M	$63.68M	$63.68M	$63.68M	$63.68M	$63.68M	$63.68M	$63.68M	$63.68M	$63.68M
Total assets	$2.94B	$2.80B	$2.77B	$2.96B	$2.95B	$2.84B	$2.68B	$2.82B	$2.84B	$2.59B	$2.49B	$2.51B
Total current liabilities	$394.28M	$373.01M	$345.70M	$394.35M	$403.77M	$399.10M	$336.11M	$373.78M	$405.64M	$370.98M	$361.93M	$411.88M
Total liabilities	$678.45M	$675.74M	$653.39M	$684.86M	$703.49M	$706.22M	$644.54M	$662.85M	$683.10M	$657.85M	$650.47M	$679.66M
Shareholders' equity	$2.26B	$2.13B	$2.12B	$2.28B	$2.24B	$2.13B	$2.03B	$2.16B	$2.16B	$1.94B	$1.84B	$1.83B

Cash flow

quarters · USD

Quarter ended	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Jan 2025	Apr 2025	Jul 2025	Oct 2025	Jan 2026	Apr 2026	Jul 2026	Oct 2026
Operating cash flow	$10.57M	$68.82M	$119.55M	$271.34M	$240.26M	$211.44M	$48.99M	$290.32M	$333.51M	$251.84M	$307.74M	$279.96M
Capital expenditures	$13.13M	$9.69M	$6.57M	$8.20M	$3.98M	$2.95M	$2.84M	$1.48M	$1.16M	$1.51M	$6.82M	$2.49M
Free cash flow	-$2.56M	$59.13M	$112.98M	$263.14M	$236.29M	$208.49M	$46.16M	$288.84M	$332.36M	$250.34M	$300.93M	$277.47M
Investing cash flow	$61.74M	$111.79M	$81.77M	-$217.15M	-$93.20M	$49.76M	$248.03M	$25.41M	$27.24M	-$51.07M	$91.43M	-$6.71M
Financing cash flow	-$206.17M	-$184.05M	-$262.42M	$5.70M	-$188.03M	-$294.82M	-$316.34M	-$103.86M	-$254.57M	-$457.11M	-$343.88M	-$249.92M
Share buybacks	$209.30M	$185.38M	$264.32M	$11.93M	$190.41M	$283.93M	$301.92M	$104.03M	$257.62M	$430.35M	$322.97M	$249.96M
Stock-based compensation	$24.31M	$19.11M	$25.35M	$23.02M	$26.35M	$25.93M	$36.07M	$30.89M	$20.10M	$29.05M	$32.56M	$28.72M
Depreciation & amortization	$6.53M	$6.38M	$7.33M	$7.45M	$7.64M	$7.34M	$7.34M	$7.42M	$6.95M	$6.95M	$6.98M	$6.93M

Quarterly figures are rebuilt from the year-to-date totals companies report — Q4 is the full year minus the first nine months, since no 10-Q is filed for it. Values are as filed; later restatements replace earlier ones. Fiscal years are labelled by the calendar year in which they end.